Seminars in Radiation Oncology
Volume 19, Issue 4 , Pages 222-228 , October 2009

Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer

  • Jennifer Specht, MD
    • ,
  • Julie R. Gralow, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Julie R. Gralow, MD, Seattle Cancer Care Alliance, 825 Eastlake Avenue East, G3-630, Seattle, WA 98109

References 

  1. Davila E, Vogel CL. Management of locally advanced breast cancer (stage III): A review. Int Adv Surg Oncol. 1984;7:297–327
  2. Zucali R, Uslenghi C, Kenda R, et al. Natural history and survival of inoperable breast cancer treated with radiotherapy and radiotherapy followed by radical mastectomy. Cancer. 1976;37:1422–1431
  3. Hortobagyi GN. Comprehensive management of locally advanced breast cancer. Cancer. 1990;66:1387–1391
  4. Caceres B, Zaharia M, Lingan M, et al. Combined therapy of stage III adenocarcinoma of the breast. Proc Am Assoc Cancer Res. 1980;21:199
  5. Knight WA, Rivkin SE, Glucksberg H, et al. Adjuvant therapy of breast cancer (The Southwest Oncology Group experience). Breast Cancer Res Treat. 1983;3:27–33
  6. Buzdar AU, Kau SW, Smith TL, et al. Ten year results of FAC adjuvant chemotherapy trial in breast cancer. Am J Clin Oncol. 1989;12:123–128
  7. Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from national surgical adjuvant breast and bowel project B18. J Natl Cancer Inst Monogr. 2001;30:96–102
  8. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: Updates of national surgical adjuvant breast and bowel project protocols B–18 and B–27. J Clin Oncol. 2008;26:778–785
  9. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis. J Natl Cancer Inst. 2005;97:188–194
  10. Hortobagyi GN, Ames FC, Buzdar AU, et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer. 1988;62:2507–2516
  11. Valagussa P, Zambetti M, Bonadonna G, et al. Prognostic factors in locally advanced noninflammatory breast cancer (Long-term results following primary chemotherapy). Breast Cancer Res Treat. 1990;15:137–147
  12. Ragaz J, Olivotto IA, Spinelli JJ, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst. 2005;97:116–126
  13. Jacquillat C, Baillet F, Weil M, et al. Results of a conservative treatment combining induction (neoadjuvant) and consolidation chemotherapy, hormonotherapy and external and interstitial irradiation in 98 patients with locally advanced breast cancer (IIIA-IIIB). Cancer. 1988;61:1977–1982
  14. Serrou B, Sancho-Garnier H, Cappelaere P, et al. Results of a randomized trial of prophylactic chemotherapy in T3-4 breast cancer patients previously treated by radiotherapy. Recent Results Cancer Res. 1978;68:105–108
  15. Bonadonna G, Valagussa P, Brambilla C, et al. Primary chemotherapy in operable breast cancer: Eight year experience of the Milan Cancer Institute. J Clin Oncol. 1998;16:93–100
  16. Hutcheon AW, Heys SD, Sarkar TK, et al. Neoadjuvant docetaxel in locally advanced breast cancer. Breast Cancer Res Treat. 2003;79(suppl 1):S19–S24
  17. Evans TRJ, Yellowlees A, Foster E, et al. phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: An Anglo-Celtic Cooperative Oncology Group study. J Clin Oncol. 2005;23:2988–2995
  18. Untch M, Konecny G, Ditsch N. Dose dense sequential epiribucin-paclitaxel as preoperative treatment of breast cancer: Results of a randomized AGO study. Proc Am Soc Clin Oncol. 2002;21:a133
  19. Therasse P, Mauriac L, Welnicka-Jaskiewicz M, et al. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin and fluorouracil with dose intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: An EORTC-NCIC-SAKK multicenter study. J Clin Oncol. 2003;21:843–850
  20. Ellis GK, Green SJ, Russell CA, et al. SWOG 0012, a randomized phase III comparison of standard doxorubicin and cyclophosphamide followed by weekly paclitaxel versus weekly doxorubicin and daily oral cyclophosphamide plus G-CSF followed by weekly paclitaxel as neoadjuvant therapy for inflammatory and locally advanced breast cancer. Proc Am Soc Clin Oncol. 2006;24:LBA537
  21. Von Minckwitz G, Kümmel S, Vogel P, et al. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early non-responsive breast cancer: phase III randomized GeparoTrio trial. J Natl Cancer Inst. 2008;100:542–551
  22. Von Minckwitz G, Kümmel S, Vogel P, et al. Intensified neoadjuvant chemotherapy in early-responding breast cancer: Phase III randomized GeparoTrio study. J Natl Cancer Inst. 2008;100:552–562
  23. Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: Enhanced response with docetaxel. J Clin Oncol. 2002;20:1456–1466
  24. Thomas E, Holmes FA, Smith TL, et al. The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to neoadjuvant doxorubicin-based regimen in women with operable breast cancer: Long-term results from a prospective randomized trial. J Clin Oncol. 2004;22:2294–2302
  25. Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol. 2001;12:1527–1532
  26. Smith IE, Dowsett M, Ebbs SR, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The immediate preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 2005;23:5108–5116
  27. Cataliotti L, Buzdar AU, Noguchi S, et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: The pre-operative “Arimidex” compared to tamoxifen (PROACT) trial. Cancer. 2006;106:2095–2103
  28. Semiglazov VF, Amiglozov V, Ivanov V, et al. The relative efficacy of neoadjuvant endocrine therapy versus chemotherapy in postmenopausal women with ER-positive breast cancer. Proc Am Soc Clin Oncol. 2004;23:a591
  29. Dowsett M, Smith IE, Ebbs SR, et al. Prognostic value of Ki67 expression after short-term pre-surgical endocrine therapy for primary breast cancer. J Natl Cancer Inst. 2007;99:167–170
  30. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a Phase III Randomized Trial. J Clin Oncol. 2001;19:3808–3816
  31. Macaskill EJ, Dixon JM. Neoadjuvant use of endocrine therapy in breast cancer. Breast J. 2007;13:243–250
  32. Bates T, Riley DL, Houghton J, et al. Breast cancer in elderly women: A cancer research campaign trial comparing treatment with tamoxifen and optimal surgery with tamoxifen alone (The Elderly Breast Cancer Working Party). Br J Surg. 1991;78:591–594
  33. Fennessy M, Bates T, MacRae K, et al. Late follow-up of a randomized trial of surgery plus tamoxifen versus tamoxifen alone in women aged over 70 years with operable breast cancer. Br J Surg. 2004;91:699–704
  34. Buzdar AU, Valero V, Ibrahim NK, et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: An update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res. 2007;13:228–233
  35. Gianni L, Eiermann W, Semiglazov V, et al: Neoadjuvant trastuzmab in patients with Her-2 positive locally advanced breast cancer: Primary efficacy analysis of the NOAH trial. Presented at the 31st Annual San Antonio Breast Cancer Symposium. San Antonio, TX, December 10-14, 2008
  36. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733–2743
  37. Spector NL, Blackwell K, Hurley J, et al. EGF103009, a phase II trial of lapatinib monotherapy in patients with relapsed/refractory inflammatory breast cancer (IBC): Clinical activity and biologic predictors of response: Presented at the ASCO Annual Meeting, Atlanta, GA, June 2-6 2006. J Clin Oncol. 2006;24(suppl):502
  38. Cristofanilli M, Boussen H, Ben Ayed F: A phase II combination study of lapatinib (TYKERB) and paclitaxel as neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer. IBC. Presented at 29th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, December 14-17, 2006
  39. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666–2676
  40. Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol. 2006;24:769–777
  41. Greil R, Moik M, Reitsamer R, et al. Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: Efficacy and safety in a phase II pilot study. Eur J Surg Oncol. 2009;July 13; [epub ahead of press]
  42. Hurvitz SA, Bosserman LD, Leland-Jones B, et al: A multicenter, double-blind randomized phase II trial of neoadjuvant treatment with single-agent bevacizumab or placebo, followed by docetaxel, doxorubicin, and cyclophosphamide (TAC), with or without bevacizumab, in patients with stage II or stage III breast cancer: Presented at ASCO Annual Meeting. Chicago, IL, May 30-June 3, 2008
  43. Feldman LD, Hortobagyi GN, Buzdar AU, et al. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res. 1986;46:2578–2581
  44. Sataloff DM, Mason BA, Prestipino AJ, et al. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: A determination of outcome. J Am Coll Surg. 1995;180:297–304
  45. Honkoop AH, Pinedo HM, de Jong JS, et al. Effects of chemotherapy on pathologic and biologic characteristics of locally advanced breast cancer. Am J Clin Pathol. 1997;107:211–218
  46. Honkoop AH, van Diest PJ, de Jong JS, et al. Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer. 1998;77:621–626
  47. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on outcome of women with operable breast cancer. J Clin Oncol. 1998;16:93–100
  48. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999;17:460–469
  49. Guarneri V, Broglio K, Kau S, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol. 2006;24:1037–1044
  50. Buzdar AU. Preoperative chemotherapy treatment of breast cancer: A review. Cancer. 2007;110:2394–2407
  51. Mazouni C, Peintinger F, Wan-Kau S, et al. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol. 2007;25:2650–2655
  52. Kuerer HM, Newman LA, Buzdar AU, et al. Residual metastatic axillary nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg. 1998;176:502–509
  53. Machiavelli MR, Romero AO, Pérez JE, et al. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Cancer J Sci. 1998;4:125–131
  54. Gajdos C, Tartter PI, Estabrook A, et al. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer. J Surg Oncol. 2002;80:4–11
  55. McCready DR, Hortobagyi GN, Kau SW, et al. The prognostic significance of lymph node metastasis after preoperative chemotherapy for advanced breast cancer. Arch Surg. 1989;124:21–25
  56. Bonadonna G, Valagussa P, Brambilla C, et al. Primary chemotherapy in operable breast cancer: Eight-year experience at the Milan Cancer Institute. J Clin Oncol. 1998;16:93–100
  57. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13:2329–2334
  58. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple negative breast cancer. J Clin Oncol. 2008;26:1275–1281
  59. Ogston KN, Miller ID, Payne S, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: Prognostic significance and survival. Breast. 2003;12:320–327
  60. Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;28:4414–4422
  61. Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National surgical adjuvant breast and bowel project protocols B–27. J Clin Oncol. 2006;24:2019–2027
  62. Colleoni M, Viale G, Zahrieh D, et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: A study of preoperative treatment. Clin Cancer Res. 2004;10:6622–6628
  63. Fisher ER, Wang J, Bryant J, et al. Pathobiology of preoperative chemotherapy findings from the national surgical adjuvant breast and bowel project (NSABP) protocols B–18. Cancer. 2002;95:681–695
  64. Faneyte IF, Schrama JG, Peterse JL, et al. Breast cancer response to neoadjuvant chemotherapy: Predictive markers and relation to outcome. Br J Cancer. 2003;88:406–412
  65. Mittendorf EA, Tucker SL, Meric-Bernstam A: Relationship between extent of estrogen receptor (ER) expression and pathologic complete response and pathologic complete response rates after administration of neoadjuvant chemotherapy: Presented at the ASCO Breast Cancer Symposium. Washington, DC, September 5-7, 2008
  66. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumors. Nature. 2000;406:747–752
  67. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869–10874
  68. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression sets. Proc Natl Acad Sci U S A. 2003;100:8418–8423
  69. Parker JS, Mullins M, Cheang MCU, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27:1160–1167
  70. Gianni L, Zambetti M, Clark K, et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol. 2005;23:7265–7277

 Dr Specht was supported by Pfizer grant IIR #GA9000S1 (CC IRB #6488) and NCCN grant (CC IRB #6489).

PII: S1053-4296(09)00042-3

doi: 10.1016/j.semradonc.2009.05.001

Seminars in Radiation Oncology
Volume 19, Issue 4 , Pages 222-228 , October 2009

Article Tools